SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001326190-24-000022
Filing Date
2024-06-26
Accepted
2024-06-26 07:33:35
Documents
15
Period of Report
2024-06-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20240625x8k.htm   iXBRL 8-K 44259
2 EX-99.1 alt-20240625xex99d1.htm EX-99.1 15607
3 GRAPHIC alt-20240625xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-24-000022.txt   193935

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20240625.xsd EX-101.SCH 3134
5 EX-101.LAB alt-20240625_lab.xml EX-101.LAB 15902
6 EX-101.PRE alt-20240625_pre.xml EX-101.PRE 10115
18 EXTRACTED XBRL INSTANCE DOCUMENT alt-20240625x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

IRS No.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 241070621
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)